drugset
drugset / Trial / NCT01103726

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

NCT01103726 ↗

Phase 1 Completed 34 enrolled Pfizer Yale University · collab
RandomizedCrossoverTriple-blindBasic science

Summary

We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.

Timeline

Start
2010-05
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MARDEPODECT Small molecule 3 mg Oral
Subject MARDEPODECT Small molecule 6 mg Oral
Subject MARDEPODECT Small molecule 15 mg Oral

Indications

No indication recorded.